246 related articles for article (PubMed ID: 32317005)
1. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus.
Nishida Y; Takahashi Y; Tezuka K; Akimoto H; Nakayama T; Asai S
BMC Pharmacol Toxicol; 2020 Apr; 21(1):28. PubMed ID: 32317005
[TBL] [Abstract][Full Text] [Related]
2. Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs - An Ab Initio Fragment Molecular Orbital Study.
Arulmozhiraja S; Matsuo N; Ishitsubo E; Okazaki S; Shimano H; Tokiwa H
PLoS One; 2016; 11(11):e0166275. PubMed ID: 27832184
[TBL] [Abstract][Full Text] [Related]
3. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.
Capuano A; Sportiello L; Maiorino MI; Rossi F; Giugliano D; Esposito K
Drug Des Devel Ther; 2013; 7():989-1001. PubMed ID: 24068868
[TBL] [Abstract][Full Text] [Related]
4. The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.
Kusunoki M; Sato D; Nakamura T; Oshida Y; Tsutsui H; Natsume Y; Tsutsumi K; Miyata T
Drug Res (Stuttg); 2016 Jan; 66(1):18-22. PubMed ID: 26125284
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Scheen AJ
Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
[TBL] [Abstract][Full Text] [Related]
7. Alogliptin; a review of a new dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus.
Said S; Nwosu AC; Mukherjee D; Hernandez GT
Cardiovasc Hematol Disord Drug Targets; 2014; 14(1):64-70. PubMed ID: 24993124
[TBL] [Abstract][Full Text] [Related]
8. Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Tebboth A; Lee S; Scowcroft A; Bingham-Gardiner P; Spencer W; Bolodeoku J; Hassan SW
Clin Ther; 2016 Aug; 38(8):1825-1832.e15. PubMed ID: 27491279
[TBL] [Abstract][Full Text] [Related]
9. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase-4 inhibitors: A population-based cohort study using Japanese Latter-Stage Elderly Healthcare Database.
Harano Y; Mitamura Y; Jiang P; Fujita T; Babazono A
J Diabetes Investig; 2023 Jun; 14(6):756-766. PubMed ID: 36897510
[TBL] [Abstract][Full Text] [Related]
10. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Kutoh E; Wada A; Terayama S
Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
[TBL] [Abstract][Full Text] [Related]
11. Effects of Concomitant Administration of a Dipeptidyl Peptidase-4 Inhibitor in Japanese Patients with Type 2 Diabetes Showing Relatively Good Glycemic Control Under Treatment with a Sodium Glucose Co-Transporter 2 Inhibitor.
Kusunoki M; Natsume Y; Miyata T; Tsutsumi K; Oshida Y
Drug Res (Stuttg); 2018 Dec; 68(12):704-709. PubMed ID: 29966149
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy.
Takayanagi R; Uchida T; Kimura K; Yamada Y
Biol Pharm Bull; 2018; 41(2):153-157. PubMed ID: 29386477
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.
Ayaori M; Iwakami N; Uto-Kondo H; Sato H; Sasaki M; Komatsu T; Iizuka M; Takiguchi S; Yakushiji E; Nakaya K; Yogo M; Ogura M; Takase B; Murakami T; Ikewaki K
J Am Heart Assoc; 2013 Jan; 2(1):e003277. PubMed ID: 23525426
[TBL] [Abstract][Full Text] [Related]
14. A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients.
Esposito K; Chiodini P; Maiorino MI; Capuano A; Cozzolino D; Petrizzo M; Bellastella G; Giugliano D
BMJ Open; 2015 Feb; 5(2):e005892. PubMed ID: 25687897
[TBL] [Abstract][Full Text] [Related]
15. Inadequate Triglyceride Management Worsens the Durability of Dipeptidyl Peptidase-4 Inhibitor in Subjects with Type 2 Diabetes Mellitus.
Shimoda M; Miyoshi-Takai M; Irie S; Tanabe A; Obata A; Okauchi S; Hirukawa H; Kimura T; Kohara K; Kamei S; Mune T; Kaku K; Kaneto H
J Diabetes Res; 2017; 2017():5856475. PubMed ID: 28626771
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus.
Tanaka K; Okada Y; Mori H; Miyazaki M; Kuno F; Sonoda S; Sugai K; Hajime M; Kurozumi A; Narisawa M; Torimoto K; Arao T; Mine S; Tanaka Y
Endocr J; 2017 Feb; 64(2):179-189. PubMed ID: 27840383
[TBL] [Abstract][Full Text] [Related]
17. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
Gibbs JP; Fredrickson J; Barbee T; Correa I; Smith B; Lin SL; Gibbs MA
J Clin Pharmacol; 2012 Oct; 52(10):1494-505. PubMed ID: 22162539
[TBL] [Abstract][Full Text] [Related]
18. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Irons BK; Weis JM; Stapleton MR; Edwards KL
Curr Diabetes Rev; 2012 May; 8(3):169-82. PubMed ID: 22429011
[TBL] [Abstract][Full Text] [Related]
19. DPP-4 inhibitors: what may be the clinical differentiators?
Gerich J
Diabetes Res Clin Pract; 2010 Nov; 90(2):131-40. PubMed ID: 20708812
[TBL] [Abstract][Full Text] [Related]
20. Distinct glucose-lowering properties in good responders treated with sitagliptin and alogliptin.
Kutoh E; Hirate M; Wada A
Int J Clin Pract; 2015 Nov; 69(11):1296-302. PubMed ID: 26194442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]